MedPath

A randomised, double blind, parallel-group study of the oxidative stress lowering effect of simvastatin and atorvastatin.

Phase 4
Conditions
arteriosclerosis
Atherosclerosis
10011082
10003216
Registration Number
NL-OMON30464
Lead Sponsor
Vrije Universiteit Medisch Centrum
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Not specified
Target Recruitment
60
Inclusion Criteria

Patients in the age between 18 and 70 years, with diabetes mellitus type 2 and/or hypertension (RR > 140/90 mmHg) and/or obesity (BMI >25) and LDL > 2,5 mmol/l.

Exclusion Criteria

Stage 5 chronic kidney disease
Use of an ACE inhibitor
Statin use in three months prior to inclusion
LDL cholesterol < 2,5 mmol/L

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>Considering that there is no gold standard to measure effect on oxidative<br /><br>stress, established parameters of oxidative stress such as oxidized LDL,<br /><br>malondealdehyde and isoprostane will be measured in plasma and urine. All<br /><br>parameters of oxidative stress before and during treatment with one of both<br /><br>statins will be compared to determine whether atorvastatin causes a stronger<br /><br>and quicker reduction of oxidative stress than simvastatin. </p><br>
Secondary Outcome Measures
NameTimeMethod
<p>Niet van toepassing</p><br>
© Copyright 2025. All Rights Reserved by MedPath